Barclays Raises Target on Eli Lilly (LLY) After Strong Tirzepatide Growth

Eli Lilly & Company (NYSE:LLY) ranks among the best stocks for a couch potato portfolio. Following worries over hepatic safety, RBC Capital reaffirmed its Outperform rating and $1,250 price target for Eli Lilly & Company on May 4. The FDA’s claim of a major hepatic failure case linked to Eli Lilly’s Foundayo was found to be unrelated to the drug following an in-house investigation.

The firm reported that one liver instance occurred in about 3,500 commercial patients, which is consistent with clinical trial results. RBC Capital stated that it will continue to monitor whether this case is part of an ongoing pattern or a one-time occurrence.

Also on the same day, in response to the company’s first-quarter 2026 results, Barclays increased its price objective for Eli Lilly & Company from $1,350 to $1,400 while keeping an Overweight rating on the company’s shares. Analyst Emily Field reported solid performance across Eli Lilly’s tirzepatide brands, including a 30% increase in international Mounjaro sales.

Barclays reduced its Foundayo forecasts for fiscal year 2026 to around $1 billion, down from the current Bloomberg average of $1.4 billion. The firm anticipates that the Foundayo retention rate vs IQVIA data will be a priority again in the current quarter.

Eli Lilly & Company is a major global pharmaceutical company that develops, manufactures, and distributes a wide range of drugs. Founded in 1876, it has grown to become one of the world’s largest pharmaceutical companies.

READ NEXT: 33 Stocks That Should Double in 3 Years and 15 Stocks That Will Make You Rich in 10 Years 

Follow Insider Monkey on Google News.